Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07409454 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

MRD-Guided BCMA/CD3 Bispecific Antibody Treatment After Stem Cell Transplant for Newly Diagnosed Multiple Myeloma

Name: MRD-Guided BCMA/CD3 Bispecific Antibody Treatment After Stem Cell Transplant for Newly Diagnosed Multiple Myeloma — clinical trial record (NCT07409454)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: CAREMM-007

StatusRecruiting

PhasePhase 2

SponsorInstitute of Hematology & Blood Diseases Hospital, China

Started2026-07-07

View on ClinicalTrials.gov ↗

Amendment history

2026-08-05

Study Status, Contacts/Locations v1

Recruitment opened

Start dateestimated 2026-03-01→confirmed 2026-07-07

Study sites0→1

2026-02-06

Original filing

Institute of Hematology & Blood Diseases Hospital, China

318 trials monitored

See 9 trials at risk

Multiple Myeloma

1,228 trials monitored

See 75 trials at risk

This is a prospective, single-arm clinical study designed to evaluate the efficacy and safety of the BCMA/CD3 bispecific antibody (CM336) as maintenance therapy after autologous hematopoietic stem cell transplantation in patients with newly diagnosed multiple myeloma.

Trial Details

NCT Number	NCT07409454
Lead Sponsor	Institute of Hematology & Blood Diseases Hospital, China
Conditions	Multiple Myeloma
Enrollment	20 participants
Start Date	2026-07-07
Primary Completion	2027-12-31 (estimated)
Study Completion	2028-12-31 (estimated)
Updated on ClinicalTrials.gov	2026-08-07